Stockscreener 앱 받기
47.92
1.05%
-0.51
전일 마감가:
$48.43
열려 있는:
$48.84
하루 거래량:
11.57M
Relative Volume:
0.91
시가총액:
$97.54B
수익:
$47.70B
순이익/손실:
$5.07B
주가수익비율:
19.32
EPS:
2.48
순현금흐름:
$14.58B
1주 성능:
-1.07%
1개월 성능:
-0.21%
6개월 성능:
-14.17%
1년 성능:
+0.63%
1일 변동 폭
$47.72
$49.11
1주일 범위
$47.72
$49.58
52주 변동 폭
$42.96
$63.33
브리스톨 마이어스 스퀴브 Stock (BMY) Company Profile
명칭
Bristol Myers Squibb Co
전화
(609) 252-4621
주소
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
BMY을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
47.92 | 98.09B | 47.70B | 5.07B | 14.58B | 2.48 |
|
LLY
Lilly Eli Co
|
711.68 | 625.77B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
179.29 | 424.47B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
210.60 | 364.92B | 58.33B | 3.73B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
126.98 | 240.07B | 53.40B | 13.68B | 16.89B | 6.9231 |
|
MRK
Merck Co Inc
|
87.37 | 210.36B | 63.43B | 16.42B | 14.72B | 6.49 |
브리스톨 마이어스 스퀴브 Stock (BMY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-05 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2025-04-22 | 개시 | Cantor Fitzgerald | Neutral |
| 2025-04-22 | 개시 | Piper Sandler | Overweight |
| 2024-12-16 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-12-10 | 재개 | BofA Securities | Neutral |
| 2024-11-15 | 개시 | Wolfe Research | Peer Perform |
| 2024-11-13 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2024-11-12 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-10-25 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-07-29 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2024-03-11 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2024-02-06 | 다운그레이드 | Redburn Atlantic | Buy → Neutral |
| 2024-01-03 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-11-15 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-11-02 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2023-10-27 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2023-10-27 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2023-10-27 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-10-20 | 재개 | UBS | Neutral |
| 2023-07-14 | 개시 | HSBC Securities | Reduce |
| 2023-07-10 | 개시 | SVB Securities | Market Perform |
| 2023-06-28 | 개시 | Daiwa Securities | Outperform |
| 2023-03-06 | 개시 | Jefferies | Hold |
| 2023-01-17 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-11-18 | 개시 | Credit Suisse | Neutral |
| 2022-10-10 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-09-14 | 다운그레이드 | Berenberg | Buy → Hold |
| 2022-06-03 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2022-04-06 | 재개 | Morgan Stanley | Underweight |
| 2021-12-17 | 개시 | Goldman | Buy |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-11-19 | 개시 | BMO Capital Markets | Outperform |
| 2021-11-01 | 다운그레이드 | Argus | Buy → Hold |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-04-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-13 | 업그레이드 | Truist | Hold → Buy |
| 2020-11-16 | 업그레이드 | Societe Generale | Hold → Buy |
| 2020-11-10 | 재개 | Bernstein | Mkt Perform |
| 2020-11-06 | 다운그레이드 | Gabelli & Co | Buy → Hold |
| 2020-10-19 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-09-29 | 개시 | Berenberg | Buy |
| 2020-07-28 | 개시 | Raymond James | Outperform |
| 2020-04-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-23 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-01-06 | 재개 | Citigroup | Buy |
| 2019-12-13 | 업그레이드 | Argus | Hold → Buy |
| 2019-11-22 | 재개 | Morgan Stanley | Equal-Weight |
| 2019-10-17 | 재개 | BofA/Merrill | Buy |
| 2019-08-14 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2019-05-28 | 개시 | Goldman | Buy |
| 2019-05-20 | 다운그레이드 | Argus | Buy → Hold |
| 2019-05-03 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2019-05-03 | 재개 | JP Morgan | Overweight |
| 2019-01-15 | 업그레이드 | Societe Generale | Sell → Buy |
| 2018-10-22 | 다운그레이드 | Citigroup | Buy → Neutral |
모두보기
브리스톨 마이어스 스퀴브 주식(BMY)의 최신 뉴스
Agilent, Bristol Myers win FDA nod for cancer test (A:NYSE) - Seeking Alpha
Questex’s Fierce Pharma Week Announces Star-Studded Lineup with Jamie-Lynn Sigler, James Van Der Beek, Selma Blair, Kelly Killoran Bensimon and John Duffield to Provide Powerful Stories of Resilience and Healing - GlobeNewswire Inc.
Bristol Myers Squibb Stock Surges on FDA Breakthrough Designation for Lung Cancer Drug Despite Ranking 217th in Trading Volume - AInvest
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields - Benzinga
Bristol Myers Squibb, SystImmune gets USFDA Breakthrough Therapy Designation for izalontamab brengitecan... - Medical Dialogues
Bristol Myers Squibb's Lung Cancer Drug Secures FDA Breakthrough Status - AInvest
Bristol Myers Squibb Company stock outlook for YEAR2025 Volume Leaders & AI Driven Stock Movement Reports - Newser
Israel issues first antitrust fine to a global pharmaceutical company - Global Competition Review
FESTIVAL ANNOUNCEMENT: 31st One Mind Music Festival (Feat. Train) Presented by Bank of America and Bristol Myers Squibb - Enidnews.com
Bristol Myers and SystImmune’s lung cancer drug gets FDA boost - Investing.com
The Zacks Analyst Blog Highlights Lowe's, Bristol-Myers Squibb, Marvell Technology and Kewaunee Scientific - Yahoo Finance
Izalontamab Brengitecan (EGFRxHER3 ADC) Granted Breakthrough Therapy Designation by U.S. FDA for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer – Company AnnouncementFT.com - Financial Times
Bristol Myers (BMY) Partners with Bain Capital to Create Immunology Therapies - uk.finance.yahoo.com
Greenlight Capital Announces Q2 2025 Trades: New Positions in FLR and VSCO, Exit From VTRS - Benzinga
Lowe's, Bristol-Myers, and Marvell Technology: Key Research Reports - AInvest
Top Research Reports for Lowe's, Bristol-Myers & Marvell Technology - Yahoo Finance
Bristol-Myers Squibb’s Promising Phase 3 Alzheimer’s Study: Market Implications - TipRanks
Bristol-Myers Squibb’s New Study on NSCLC Treatment: Market Implications - TipRanks
Layoff Tracker: Bausch Health Closes California Site, Cuts 49 Employees - BioSpace
Bristol-Myers Squibb’s Promising Phase 3 Study on Deucravacitinib for Sjögren’s Syndrome - TipRanks
Bristol-Myers Squibb and Incyte’s Cancer Study Update: Market Implications - TipRanks
Pfizer and Bristol-Myers Squibb’s Promising Study on Multiple Myeloma Treatment - TipRanks
Bristol-Myers Squibb’s New Psoriasis Study: A Long-Term Safety Evaluation - TipRanks
Anal Cancer Market Is Going to Boom | Major Giants Merck & Co., Roche, Bristol-Myers Squibb, Pfizer - newstrail.com
Bristol-Myers Squibb stock price target lowered to $45 at Cantor Fitzgerald - Investing.com Nigeria
Testicular Cancer Market Analysis and Forecast Report 2025-2035 | Competitive Analysis of Bristol Myers Squibb, Pfizer, Eli Lilly, Merck, Novartis, Amgen, F. Hoffmann-La RocheResearchAndMarkets.com - Bluefield Daily Telegraph
Multiple Myeloma Market Trends and Company Analysis Report 2025-2033 Featuring BMS, Novartis, Abbvie, Sanofi, Johnson and Johnson, Baxter, Pfizer, and Takeda - uk.finance.yahoo.com
Can Bristol Myers Squibb Company lead its sector in growthHigh Yield Growth Opportunities - mustnews.co.kr
Hung Trinh: BioNTech SE and Bristol Myers Squibb Partner on Next-Gen Bispecific Antibody for Solid Tumors - Oncodaily
Bristol-Myers Squibb’s MYK-224 Study Termination: What Investors Need to Know - MSN
Yan Leyfman: FDA Accepts Bristol Myers Squibb's Breyanzi for Priority Review as a Potential Treatment for Relapsed MZL - Oncodaily
Jim Cramer on Bristol-Myers: “Have Not Been Recommending the Stock” - Insider Monkey
Bristol-Myers Squibb Stock: Is BMY Outperforming the Healthcare Sector? - MSN
Bristol Myers Squibb Named Top Dividend Stock With Insider Buying and 5.47% Yield (BMY) - Nasdaq
Bristol-Myers Squibb’s Promising Phase 3 Study on BMS-986278: A Potential Game-Changer for Pulmonary Fibrosis - TipRanks
Bristol Myers Squibb (NYSE:BMY) Cut to Neutral at Daiwa Capital Markets - Defense World
Car T Cell Therapy For Multiple Myeloma Market Growth to Accelerate in Forecast Period (2024-2032), DelveInsight Analyzes by DelveInsight | Johnson & Johnson, Gadeta, Bristol-Myers Squibb, Bluebird - Barchart.com
Stock Analysis | Bristol-Myers Squibb OutlookNavigating Weak Technicals Amid Mixed Fundamentals - AInvest
FDA Accepts Breyanzi sBLA from Bristol Myers Squibb and Grants It Priority Review for MZL - BioPharm International
Bristol Myers Squibb Q1 2025 slides: portfolio transformation gains momentum as guidance raised - Investing.com Nigeria
Bristol Myers Squibb Q1 2025 slides: portfolio transformation gains momentum as guidance raised By Investing.com - Investing.com South Africa
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
3 Dividend Stocks for August 2025 - Morningstar
Bristol Myers Beats on Q2 Earnings and Sales, Raises '25 Sales View - MSN
Bristol Myers Squibb: Why I'm Pounding The Table On This Buying Opportunity (NYSE:BMY) - Seeking Alpha
BioNTech Outlines Development Plan For PD-L1xVEGF-Targeting BNT-327 - insights.citeline.com
Morgan Stanley Maintains a Sell Rating on Bristol-Myers Squibb Company (BMY) - Insider Monkey
Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas - Yahoo Finance
BioNTech shares rise over 2% as Q2 revenue doubles, Bristol Myers deal bolsters outlook - Investing.com
Bristol-Myers Squibb: Is the 30% Pullback a Strategic Buy Opportunity? - AInvest
Bristol-Myers Squibb (BMY) Stock Analysis: Exploring a 22.84% Upside Potential with a Robust Dividend Yield - DirectorsTalk Interviews
브리스톨 마이어스 스퀴브 (BMY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.46%
1.18%
자본화:
|
볼륨(24시간):